<DOC>
	<DOCNO>NCT02220335</DOCNO>
	<brief_summary>A number 100 patient pulmonary arterial hypertension associate leave Heart failure schedule elective pulmonary arterial denervation ( PADN ) randomize 1:1 either PADN control group .</brief_summary>
	<brief_title>Pulmonary Arterial Denervation Patients With Pulmonary Arterial Hypertension Associated With Left Heart Failure</brief_title>
	<detailed_description>Heart failure patient must complete right heart catheterization . All patient accept optimal medical therapy , include diuretic , Nitrate ester , β-blockers , ACE inhibitor receptor blocker aldosterone antagonists and/or digoxin ) .The patient pulmonary hypertension define two group : `` passive '' pulmonary hypertension ( mPAP≥25 mmHg , PCWP &gt; 15 mmHg pulmonary vascular resistance &lt; 2.5 wood unit ) increase due backward transmission increase leave ventricular filling pressure , `` reactive '' pulmonary hypertension ( mPAP≥25 mmHg , PCWP &gt; 15 mmHg pulmonary vascular resistance ≥2.5 wood unit ) increase resistance due either pulmonary vasoconstriction structural change pulmonary vasculature . All `` reactive '' pulmonary hypertension patient eligible randomize study PADN group control group accord computer generate random table .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<criteria>Age &gt; 18yr `` Reactive '' Pulmonary Hypertension Left Heart Failure : mPAP≥25 mmHg , PCWP &gt; 15 mmHg pulmonary vascular resistance ( PVR ) [ The PVR = ( mPAPPCWP ) / carbon monoxide ] &gt; 2.5 wood unit Voluntary acceptance followup assessment program requirement . WHO group I , III , IV , V pulmonary artery hypertension Severe Renal dysfunction ( Ccr &lt; 30 ml/min ) Blood platelet count &lt; 100,000/L Expected life span &lt; 12month In pregnancy Systematical inflammation Malignant cancer ( ) Tricuspid valve stenosis , Suprapulmonary valve stenosis Allergic study drug metal material</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>pulmonary hypertension</keyword>
	<keyword>pulmonary arterial denervation</keyword>
	<keyword>left heart failure</keyword>
	<keyword>6-min walk distance</keyword>
</DOC>